288 related articles for article (PubMed ID: 20233971)
1. Mast cells and the neurofibroma microenvironment.
Staser K; Yang FC; Clapp DW
Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
[TBL] [Abstract][Full Text] [Related]
2. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.
Yang FC; Ingram DA; Chen S; Zhu Y; Yuan J; Li X; Yang X; Knowles S; Horn W; Li Y; Zhang S; Yang Y; Vakili ST; Yu M; Burns D; Robertson K; Hutchins G; Parada LF; Clapp DW
Cell; 2008 Oct; 135(3):437-48. PubMed ID: 18984156
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
Staser K; Yang FC; Clapp DW
Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
[TBL] [Abstract][Full Text] [Related]
4. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.
Staser K; Yang FC; Clapp DW
Curr Opin Hematol; 2010 Jul; 17(4):287-93. PubMed ID: 20571392
[TBL] [Abstract][Full Text] [Related]
5. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
[TBL] [Abstract][Full Text] [Related]
6. The plexiform neurofibroma microenvironment.
Yang FC; Staser K; Clapp DW
Cancer Microenviron; 2012 Dec; 5(3):307-10. PubMed ID: 22821631
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
8. Treatment for plexiform neurofibromas in patients with NF1.
Ardern-Holmes SL; North KN
Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
[No Abstract] [Full Text] [Related]
9. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs.
Le LQ; Parada LF
Oncogene; 2007 Jul; 26(32):4609-16. PubMed ID: 17297459
[TBL] [Abstract][Full Text] [Related]
10. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
12. Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications.
Gottfried ON; Viskochil DH; Fults DW; Couldwell WT
Neurosurgery; 2006 Jan; 58(1):1-16; discussion 1-16. PubMed ID: 16385324
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.
Yang FC; Ingram DA; Chen S; Hingtgen CM; Ratner N; Monk KR; Clegg T; White H; Mead L; Wenning MJ; Williams DA; Kapur R; Atkinson SJ; Clapp DW
J Clin Invest; 2003 Dec; 112(12):1851-61. PubMed ID: 14679180
[TBL] [Abstract][Full Text] [Related]
14. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
15.
Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
[TBL] [Abstract][Full Text] [Related]
16. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of
Burks CA; Rhodes SD; Bessler WK; Chen S; Smith A; Gehlhausen JR; Hawley ET; Jiang L; Li X; Yuan J; Lu Q; Jacobsen M; Sandusky GE; Jones DR; Clapp DW; Blakeley JO
Mol Cancer Ther; 2019 Dec; 18(12):2321-2330. PubMed ID: 31527226
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromas in NF1: Schwann cell origin and role of tumor environment.
Zhu Y; Ghosh P; Charnay P; Burns DK; Parada LF
Science; 2002 May; 296(5569):920-2. PubMed ID: 11988578
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
19. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.
Rutkowski JL; Wu K; Gutmann DH; Boyer PJ; Legius E
Hum Mol Genet; 2000 Apr; 9(7):1059-66. PubMed ID: 10767330
[TBL] [Abstract][Full Text] [Related]
20. New insights into the neurofibroma tumor cells of origin.
Li S; Chen Z; Le LQ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i13-i22. PubMed ID: 32642729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
